Celltrion Reports Positive Data For High-Concentration Adalimumab

Phase III Trials Cover Two Delivery Methods For CT-P17

Celltrion’s phase III study comparing the pharmacokinetics, efficacy and safety profile of its CT-P17 high-concentration adalimumab biosimilar to Humira has yielded positive results. The company is presenting the results at the American College of Rheumatology Convergence 2020.

Needle pen
Celltrion’s trials demonstrated the safety and efficacy of its high-concentration adalimumab biosimilar • Source: Shutterstock

Celltrion, Inc. has reported positive data after a 24-week study which found that its CT-P17 proposed high-concentration adalimumab biosimilar is comparable to the Humira reference brand in the treatment of rheumatoid arthritis patients. 

The South Korean company’s Phase III study found that the company’s 100mg/ml citrate-free adalimumab formulation was safe and equivalent for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products